- Home
- AVIR vs TTGT Comparison
AVIR vs TTGT Comparison
Compare AVIR & TTGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | TTGT |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.0M | 344.2M |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AVIR | TTGT |
|---|---|---|
| Price | $6.08 | $4.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.00 | ★ $11.25 |
| AVG Volume (30 Days) | ★ 569.0K | 527.8K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $351,367,000.00 | N/A |
| Revenue This Year | N/A | $74.33 |
| Revenue Next Year | N/A | $3.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.46 | $3.41 |
| 52 Week High | $6.45 | $15.54 |
Technical Indicators
Market Signals| Indicator | AVIR | TTGT |
|---|---|---|
| Relative Strength Index (RSI) | 76.99 | 46.18 |
| Support Level | $3.33 | $3.41 |
| Resistance Level | N/A | $5.88 |
| Average True Range (ATR) | 0.31 | 0.36 |
| MACD | 0.12 | 0.06 |
| Stochastic Oscillator | 79.43 | 50.35 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.